gp130/IL6ST Protein, Rat (HEK293, His)

Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family^[1]. gp130 inhibits the cell growth and migration^[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity^[4][5]. gp130/IL6ST Protein, Rat (HEK293, His) is a recombinant protein with a His label that consists of 614 amino acids (M4-E618) and is produced by HEK293 cells.

Glycoprotein 130 mRNA is ubiquitously expressed in the human body,exhibiting highest levels in saphenous vein, pericardium, ovary, omental adipose tissue, peritoneum, spleen lymphnodes, and trigeminal ganglia. And gp130 expression is significantly increased in adult organs compared to fetal organs. Moreover, gp130 is highly expressed in multiple types of cancers compared to normal tissues^[3].
The amino acid sequence of human gp130 protein has low homology between mouse and rat gp130 protein.
gp130 signaling is initiated when autocrine or paracrine cyto-kines induce the dimerization of gp130 and an α-receptor subunit to form the receptor complex, leading to185the activation of downstream signaling cascades, such as the JAK/STAT, the PI3K/Akt, and the Ras/Raf/Mek/Erk1/2MAPK pathways. The activation of JAK/Stat3 pathway induces its target gene expression, resulting in cell growth and proliferation (cyclin D, CDC25 A, c-Myc, survivin), survival (survivin, Bcl-2, Bcl-X_L), angiogenesis (VEGF), and cell migration (MMP-2, MMP-7, and MMP-9)^[3]. gp130 is a IL-6 antagonist shows anti-tumor, anti-inflammation and antinociceptive activity^[4]. gp130 decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67^[5].

Immobilized Human gp130, His Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately 4.94 ng/mL.

• 
  Immobilized Human gp130, His Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately 4.94 ng/mL.

Rat

HEK293

C-His

NP_001008725.2 (Q23-E618)

25205  [NCBI]

Partial

QLVEPCGYIYPEFPVVQRGSNFTATCVLKEKCLQVYSVNATYIVWKTNHVAVPKEQVTVINRTASSVTFTDVVFQNVQLTCNILSFGQIEQNVYGITILSGYPPDIPTNLSCIVNEGKNMLCQWDPGRETYLETNYTLKSEWATEKFPDCRTKHGTSSCMMGYTPIYFVNIEVWVEAENALGNVSSEPINFDPVDKVKPSPPHNLSVTNSEELSSILKLAWVNSGLDSILRLKSDIQYRTKDASTWIQVPLEDTVSPRTSFTVQDLKPFTEYVFRIRSIKENGKGYWSDWSEEASGTTYEDRPSKAPSFWYKVNANHPQEYRSARLIWKTLPLSEANGKILDYEVVLTQSKSVSQTYTVNGTELIVNLTNNRYVASLAARNVVGKSPATVLTIPGSHFKASHPVVDLKAFPKDNLLWVEWTPPSKPVNKYILEWCVLSENSPCIPDWQQEDGTVNRTHLRGSLLESKCYLITVTPVFPGGPGSPESMKAYLKQAAPSKGPTVRTKKVGKNEAVLEWDHLPVDVQNGFIRNYSISYRTSVGKEMVVRVDSSHTEYTLSSLSSDTLYMVHMAAYTEEGGKDGPEFTFTTLKFAQGEIE

Approximately 90-100 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Cao Y, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016 Dec 5;6:38364.  [Content Brief]

  [2]. Nogueira-Silva C, et al. The role of glycoprotein 130 family of cytokines in fetal rat lung development. PLoS One. 2013 Jun 24;8(6):e67607.  [Content Brief]

  [3]. Xu S, et al. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013 Nov;17(11):1303-28.  [Content Brief]

  [4]. Boettger MK, et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010;12(4):R140.  [Content Brief]

  [5]. Hong J, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016 Apr 15;6:24397.  [Content Brief]